In spite of widely available different antidepressants, major depression does not respond adequately in up to one third of patients. Overall, the need for both reliable and well-tolerated treatment has remained unmet for a sizeable proportion of people with depression. In the past couple of years, there has been controversy about the suitability of Agomelatine (Valdoxan) [read the full story…]